Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody. The company was founded in 2016 and is headquartered in Waltham, Massachusetts.
Frequently asked questions
What sector does Xilio Development Inc (XLO) operate in?
Xilio Development Inc belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Xilio Development Inc (XLO) current stock price?
As of the latest data, Xilio Development Inc stock price is $7.31, with a previous close of $7.57. Xilio Development Inc lost -$0.26 in the last trading session, representing a -3.43% loss.
What is Xilio Development Inc (XLO) current market capitalization?
Xilio Development Inc market cap is approximately 48.10 million.
What is Xilio Development Inc (XLO) Earnings Per Share (EPS)?
The trailing EPS is -$0.32, and the forward EPS is -$2.23.
What is Xilio Development Inc (XLO) EBITDA?
Xilio Development Inc EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -6.04 million.
Does Xilio Development Inc (XLO) pay dividends?
No. Xilio Development Inc does not pay a dividend.
How did Xilio Development Inc (XLO) perform in its most recent earnings report?
In the last report (June 30, 2026), Xilio Development Inc posted an EPS surprise of 44.07% and a revenue surprise of 46.95%.
When is Xilio Development Inc (XLO) next earnings report?
Xilio Development Inc is expected to release its next earnings report on September 30, 2026.
What is Xilio Development Inc (XLO) beta (volatility) score?
Xilio Development Inc has a beta of -0.118, indicating lower volatility than the overall market.
